Loading...
XSTO
IDLDX
Market cap13mUSD
May 26, Last price  
0.57SEK
Name

AroCell AB (publ)

Chart & Performance

D1W1MN
XSTO:IDLDX chart
P/E
P/S
2.30
EPS
Div Yield, %
Shrs. gr., 5y
41.80%
Rev. gr., 5y
164.62%
Revenues
57m
+33.45%
26,8540000460,21754,606502,033781,841442,69784,00011,996,00036,986,00043,039,00057,436,000
Net income
-42m
L-28.41%
-2,152,234-3,584,151-3,156,941-3,732,929-6,368,852-7,478,995-9,234,943-17,270,758-20,757,029-16,201,966-19,459,000-50,026,000-58,973,000-59,297,000-42,449,000
CFO
-2m
L-82.45%
-2,593,000000-9,127,552-7,167,532-15,235,183-16,407,394-15,055,220-18,902,000-28,206,000-13,694,000-13,436,000-2,358,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

AroCell AB (publ) is an in vitro diagnostics enterprise primarily focused on the surveillance of various cancerous conditions, such as hematological malignancies, breast cancer, and other solid tumors. The company develops, produces, and markets its flagship product, AroCell TK 210 ELISA, an immunoassay kit designed for measuring Thymidine Kinase 1 levels in human blood. Additionally, AroCell provides TUBEX TF, a rapid bacteriological test for the detection of typhoid fever. Founded in 2000, the firm was originally known as Xi Bao Research AB, adopting its current name, AroCell AB (publ), in 2006. It maintains its headquarters in Uppsala, Sweden.
IPO date
May 25, 2011
Employees
26
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT